bristoldrv Posted July 29, 2019 Report Share Posted July 29, 2019 Pfizer agrees to spin off its off-patent drug business and combine it with Mylan The Washington PostPfizer has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan, a move that leaves Pfizer with its more ... View the full article Quote Link to comment Share on other sites More sharing options...